The Technical Analyst
Exact Sciences Corp [EXAS]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Exact Sciences Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-3.97% $60.96
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 11 066 mill |
| EPS: | -1.130 |
| P/E: | -53.95 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 181.53 mill |
| Avg Daily Volume: | 2.42 mill |
| RATING 2024-04-19 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -53.95 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.88x |
| Company: PE -53.95 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 58.22 - 63.70 ( +/- 4.49%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Condella Sarah | Sell | 2 000 | Common Stock |
| 2024-04-02 | Baranick Brian | Sell | 924 | Common Stock |
| 2024-03-28 | Condella Sarah | Sell | 2 000 | Common Stock |
| 2024-02-29 | Orville Jacob A | Buy | 4 724 | Common Stock |
| 2024-03-01 | Orville Jacob A | Sell | 2 154 | Common Stock |
| INSIDER POWER |
|---|
| 36.33 |
| Last 100 transactions |
| Buy: 542 709 | Sell: 252 987 |
Forecast:
16:00 - $60.97
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $60.97
Forecast 2: 16:00 - $60.97
Forecast 3: 16:00 - $60.97
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $60.96 (-3.97% ) |
| Volume | 2.09 mill |
| Avg. Vol. | 2.42 mill |
| % of Avg. Vol | 86.35 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EXAS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $60.93 | N/A | Active |
|---|
EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Latest Press Releases
2024-04-15 06:00:00 - Press Release
Exact Sciences Names Aaron Bloomer As New Chief Financial Officer
Madison, wis.--(business wire)--exact sciences (nasdaq: exas), a leading provider of cancer screening and diagnostic tests, announced today the appointment of aaron bloomer as chief financial officer (cfo), effective may 15, 2024. mr. bloomer brings to exact sciences more than 15 years of finance and accounting experience. he previously held leadership positions at baxter international and 3m, where he helped improve financial results, drove operational rigor, led strategic growth initiatives,.
2024-04-11 06:00:00 - Press Release
Exact Sciences Announces Debt Exchange Transaction And Private Placement Of Convertible Senior Notes
Madison, wis.--(business wire)--exact sciences corp. (nasdaq: exas) (the “company”), a leading provider of cancer screening and diagnostic tests, today announced that on april 10, 2024 it entered into privately negotiated exchange and purchase agreements (the “agreements”) with certain holders of the company's 0.3750% convertible senior notes due 2028 (the “existing notes”). pursuant to the agreements, the company has agreed to issue to the holders $620.7 million aggregate principal amount of a.
2024-04-08 12:05:00 - Press Release
Exact Sciences To Present Late-breaking Data From Ascend-2 Study Validating Its Investigational Multi-cancer Early Detection Test At Aacr Annual Meeting 2024
Madison, wis.--(business wire)--exact sciences corp. (nasdaq: exas), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ascend-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (mced) blood test. these results validate the sensitivity and specificity of the company's multi-biomarker class approach across a broad range of cancer types, including the m.
2024-04-08 06:00:00 - Press Release
Exact Sciences Schedules First Quarter 2024 Earnings Call
Madison, wis.--(business wire)--exact sciences corp. (nasdaq: exas), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the u.s. financial markets on may 8, 2024. following the release, company management will host a webcast and conference call at 5 p.m. et to discuss financial results and business progress. first quarter 2024 webcast & conference call details date: wedn.
2024-04-04 06:05:00 - Press Release
Exact Sciences To Provide Mayo Clinic Patients With Individualized Cancer Tumor Information To Inform Treatment
Rochester, minn. & madison, wis.--(business wire)--exact sciences and mayo clinic advance precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients.
Latest News
2024-04-17 19:21:25 - Zacks Investment Research
Why Exact Sciences (EXAS) Dipped More Than Broader Market Today
Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.
2024-04-10 16:31:04 - Zacks Investment Research
3 Buy-Rated Stocks Flexing Relative Strength
While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three carrying a favorable Zacks Rank.
2024-04-08 12:05:00 - Business Wire
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company's multi-biomarker class approach across a broad range of cancer types, including the m.
2024-04-08 06:00:00 - Business Wire
Exact Sciences Schedules First Quarter 2024 Earnings Call
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2024 webcast & conference call details Date: Wedn.
2024-04-05 16:16:35 - InvestorPlace
The 3 Best Cathie Wood Stocks to Buy in April 2024
Full disclosure, I'm not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks.
2024-04-04 10:15:00 - The Motley Fool
1 Beaten-Down Cathie Wood Stock to Buy and Hold
Exact Sciences' most important product is still driving top-line growth. The company is working on several other exciting diagnostic tests.
2024-04-03 11:01:09 - Zacks Investment Research
Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.
2024-03-26 09:51:03 - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
2024-03-25 10:56:06 - Zacks Investment Research
How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%
The mean of analysts' price targets for Exact Sciences (EXAS) points to a 53.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-03-22 12:36:44 - Zacks Investment Research
Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?
